Capital Management, Llcadar... Net Worth

The estimated Net Worth of Capital Management, Llcadar... is at least $264 Tysiąc dollars as of 9 August 2024. Capital Llcadar owns over 6,000 units of Pieris Pharmaceuticals Inc stock worth over $263,522 and over the last few years Capital sold PIRS stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Capital Llcadar PIRS stock SEC Form 4 insiders trading

Capital has made over 1 trades of the Pieris Pharmaceuticals Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently Capital bought 6,000 units of PIRS stock worth $92,340 on 9 August 2024.

The largest trade Capital's ever made was buying 6,000 units of Pieris Pharmaceuticals Inc stock on 9 August 2024 worth over $92,340. On average, Capital trades about 6,000 units every 0 days since 2024. As of 9 August 2024 Capital still owns at least 15,067 units of Pieris Pharmaceuticals Inc stock.

You can see the complete history of Capital Llcadar stock trades at the bottom of the page.

What's Capital Llcadar's mailing address?

Capital's mailing address filed with the SEC is 3503 WILD CHERRY DRIVE3503 WILD CHERRY DRIVE, BUILDING 9BUILDING 9, AUSTINAUSTIN, TXTX, 7873878738.

Insiders trading at Pieris Pharmaceuticals Inc

Over the last 9 years, insiders at Pieris Pharmaceuticals Inc have traded over $24,745,707 worth of Pieris Pharmaceuticals Inc stock and bought 1,154,000 units worth $3,376,410 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Advisors Llc Orbi Med Capit... oraz Chau Quang Khuong. On average, Pieris Pharmaceuticals Inc executives and independent directors trade stock every 144 days with the average trade being worth of $4,572,148. The most recent stock trade was executed by Capital Management, Llcadar... on 9 August 2024, trading 6,000 units of PIRS stock currently worth $92,340.

What does Pieris Pharmaceuticals Inc do?

pieris pharmaceuticals is a clinical stage biotechnology company that discovers and develops anticalin-based drugs to target validated disease pathways in a unique and transformative way. our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled anticalin to treat uncontrolled asthma and a half-life-optimized anticalin to treat anemia. proprietary to pieris, anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. our libraries of more than 100 billion different anticalin proteins have repeatedly delivered drug candidates binding to a very broad spectrum of therapeutic targets. pieris has established a diverse pipeline of anticalin therapeutics for a number of different indications and has r&d collaborations with roche

Complete history of Capital Llcadar stock trades at Pieris Pharmaceuticals Inc

Pieris Pharmaceuticals Inc executives and stock owners

Pieris Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Stephen Yoder,
  President, Chief Executive Officer, Director
• Hitto Kaufmann,
  Senior Vice President, Chief Scientific Officer
• Stephen S. Yoder J.D.,
  CEO, Pres & Director
• Stephen S. Yoder,
  CEO, Pres & Director
• Dr. Hitto Kaufmann Ph.D.,
  Sr. VP & Chief Scientific Officer
• Dr. Tim Demuth M.D., Ph.D.,
  Sr. VP & Chief Medical Officer
• Thomas Bures,
  Sr. VP & CFO
• james Geraghty,
  Independent Chairman of the Board
• Christopher Kiritsy,
  Independent Director
• Peter Kiener,
  Independent Director
• Matthew Sherman,
  Independent Director
• Michael Richman,
  Independent Director
• Ann Barbier,
  Independent Director
• Maya Said,
  Independent Director
• Maria Kelman,
  Director of Investor Relations
• Shane Olwill,
  Senior Vice President - Head of Translational Science
• Eckhard Niemeier,
  Senior Vice President - Head of Business Development
• Ingmar Bruns,
  Senior Vice President - Head of Clinical Development
• Ahmed Mousa,
  Senior Vice President - Corporate Operations , General Counsel, Secretary
• Thomas Bures,
  Chief Financial Officer, Principal Accounting Officer, Vice President - Finance, Treasurer
• Dr. Shane Olwill Ph.D.,
  Sr. VP & Chief Devel. Officer
• Ahmed S. Mousa J.D.,
  Sr. VP, Chief Bus. Officer, Gen. Counsel & Corp. Sec.
• Prompong Chaikul,
  Chief Supply Chain Officer
• Dr. Christine Rothe,
  Head of Discovery & Alliance Management and VP
• Frank Vollmering,
  VP of HR
• Advisors Llc Orbi Med Capit...,
  
• Jean Pierre Bizzari,
  
• Claude Knopf,
  Chief Business Officer
• Steven Prelack,
  Director
• Julian Adams,
  
• Louis Matis,
  SVP, Chief Development Officer
• Darlene M Deptula Hicks,
  Sr. Vice President and CFO
• Chau Quang Khuong,
  Director
• Advisors Llc Orbi Med Capit...,
  
• Allan Reine,
  Chief Financial Officer
• Partners L P/Ilbiotechnolog...,
  
• Capital Management, Llc Aquilo,
  10% owner
• Tim Demuth,
  Chief Medical Officer
• Capital Management, Llcadar...,